Trial reportKidney3602020
Randomized, Placebo-Controlled Trial of Rifaximin Therapy for Lowering Gut-Derived Cardiovascular Toxins and Inflammation in CKD.
Trial report in Kidney360, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02342639 (Impact of Rifaximin Therapy on Intestinal Byproducts in Chronic Kidney Disease), which is not on this map. Cited by 18 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Impact of Rifaximin Therapy on Intestinal Byproducts in Chronic Kidney Disease
Who cites it
18 citing papers in PubMed, 2 syntheses or guidelines pooled it, 21 citations in OpenAlex.
- The Gut-Heart Axis: Effects of Intestinal Microbiome Modulation on Cardiovascular Disease-Ready for Therapeutic Interventions?International journal of molecular sciences · 2024Pooled it
- The Links between Microbiome and Uremic Toxins in Acute Kidney Injury: Beyond Gut Feeling-A Systematic Review.Toxins · 2020Pooled it
- The Gut Microbiota-Metabolite-Host Axis in Cardiometabolic Diseases: Bridging Bench to Bedside.Cardiovascular drugs and therapy · 2026Review
- Gut microbiota‑derived metabolites in cardiovascular disease: Focus on trimethylamine N‑oxide, short‑chain fatty acids and bile acids (Review).Molecular medicine reports · 2026Review
- Gut-kidney axis: Dysbiosis and renal disease.World journal of nephrology · 2026Review
- Modulation of gut microFLORA with rifaximin to reduce high platelet reactivity in post-ACS patients on ticagrelor: rationale and design of the FLORA-ACS study.Cardiology journal · 2026Article
- Clinical Pharmacokinetic-Pharmacodynamic Relationships of Pharmacological Strategies for Attenuating p-Cresyl Sulfate in Patients with Kidney Disease.Clinical pharmacokinetics · 2025Article
- Gut-Adipose Tissue Axis and Metabolic Health.Current issues in molecular biology · 2025Review
- Gut microbiota therapy for chronic kidney disease.Frontiers in immunology · 2025Review
- Gut microbiota on cardiovascular diseases-a mini review on current evidence.Frontiers in microbiology · 2025Review
- The gut-kidney axis in chronic kidney disease: mechanisms, microbial metabolites, and microbiome-targeted therapeutics.Frontiers in medicine · 2025Review
- Microbiome-Derived Trimethylamine N-Oxide (TMAO) as a Multifaceted Biomarker in Cardiovascular Disease: Challenges and Opportunities.International journal of molecular sciences · 2024Review
- Sarcopenia in cirrhosis: Prospects for therapy targeted to gut microbiota.World journal of gastroenterology · 2023Review
- Gut Microbiota in Chronic Kidney Disease: From Composition to Modulation towards Better Outcomes-A Systematic Review.Journal of clinical medicine · 2023Review
- Untargeted Metabolomics Analysis Using UHPLC-Q-TOF/MS Reveals Metabolic Changes Associated with Hypertension in Children.Nutrients · 2023Article
- Targeting innate immunity-driven inflammation in CKD and cardiovascular disease.Nature reviews. Nephrology · 2022Review
- Metabolic control by the microbiome.Genome medicine · 2022Review
- The Microbiome and Uremic Solutes.Toxins · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 4 institutions in 1 country.
Funding
Abstract
backgroundRecent evidence suggests the systemic accumulation of by-products of gut microbes contributes to cardiovascular morbidity in patients with CKD. Limiting the generation of toxic bacterial by-products by manipulating the intestinal microbiota may be a novel strategy for reducing cardiovascular disease in CKD. Rifaximin is a minimally absorbed, oral antibiotic that targets intestinal pathogens and is commonly used as chronic therapy for the prevention of encephalopathy in patients with cirrhosis.
methodsWe conducted a randomized, double-blinded, placebo-controlled trial to determine the effect of a 10-day course of oral rifaximin 550 mg BID versus placebo on circulating concentrations of gut-derived cardiovascular toxins and proinflammatory cytokines in patients with stage 3-5 CKD (
resultsA total of 19 patients were randomized to each of the rifaximin and placebo arms, with
conclusionsShort-term rifaximin treatment failed to reduce gut-derived cardiovascular toxins and inflammatory cytokines in patients with CKD. CLINICAL TRIAL REGISTRY NAME AND REGISTRATION NUMBER: Rifaximin Therapy in Chronic Kidney Disease, NCT02342639.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.